Inhibitor Therapeutics (INTI) Operating Expenses (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Operating Expenses came in at $695632.0 in Q1 2026, up 3.13% YoY from $674551.0 in Q1 2025, and down 47.1% on a QoQ basis from $1.3 million in Q4 2025.
Inhibitor Therapeutics (INTI) Operating Expenses (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Operating Expenses data on file, last reported at $695632.0 in Q1 2026.
- Quarterly Operating Expenses rose 3.13% year-over-year to $695632.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 3.08% YoY) and the FY2025 annual result came in at $3.4 million, down 6.31% from the prior year.
- Operating Expenses slipped to $695632.0 in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $1.5 million in Q4 2024 to a low of $69987.0 in Q3 2022.
- A 5-year average of $696623.5 and a median of $695773.0 in 2025 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 1373.05% in 2022, down 44.26% in 2022.
- Tracing INTI's Operating Expenses over 5 years: stood at $423635.0 in 2022, then jumped by 200.56% to $1.3 million in 2023, then grew by 16.57% to $1.5 million in 2024, then retreated by 11.4% to $1.3 million in 2025, then slumped by 47.1% to $695632.0 in 2026.
- The last three Operating Expenses figures came in at $695632.0 (Q1 2026), $1.3 million (Q4 2025), and $741215.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 541.02 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | 618,597.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 695,632.00 |
| Dec 31, 2025 | 1.32 Mn |
| Sep 30, 2025 | 741,215.00 |
| Jun 30, 2025 | 695,773.00 |
| Mar 31, 2025 | 674,551.00 |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 813,196.00 |
| Jun 30, 2024 | 585,147.00 |
| Mar 31, 2024 | 774,817.00 |
| Dec 31, 2023 | 1.27 Mn |
| Sep 30, 2023 | 759,528.00 |
| Jun 30, 2023 | 742,461.00 |
| Mar 31, 2023 | 629,724.00 |
| Dec 31, 2022 | 423,635.00 |
| Sep 30, 2022 | 69,987.00 |
| Jun 30, 2022 | 70,804.00 |
| Mar 31, 2022 | 93,500.00 |
| Dec 31, 2021 | 28,759.00 |
| Sep 30, 2021 | 66,248.00 |
| Jun 30, 2021 | 62,635.00 |